B-cell Malignancies clinical trials at UCSF
1 research study open to eligible people
A Safety and Efficacy Study Evaluating CTX110 in Subjects With Relapsed or Refractory B-Cell Malignancies (CARBON)
open to eligible people ages 18 years and up
This is an open-label, multicenter, Phase 1 study evaluating the safety and efficacy of CTX110 in subjects with relapsed or refractory B-cell malignancies.
San Francisco, California and other locations